| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K01737880 | CTRPv2 | pan-cancer | AAC | 0.22 | 0.09 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | -0.08 | 0.09 |
| mRNA | SGC0946 | GDSC1000 | pan-cancer | AAC | -0.061 | 0.09 |
| mRNA | GSK690693 | GDSC1000 | pan-cancer | AAC | 0.054 | 0.09 |
| mRNA | CMK | GDSC1000 | pan-cancer | AAC | 0.092 | 0.09 |
| mRNA | BRD-A71883111 | CTRPv2 | pan-cancer | AAC | -0.066 | 0.09 |
| mRNA | bid1870 | gCSI | pan-cancer | AAC | 0.099 | 0.09 |
| mRNA | QS11 | GDSC1000 | pan-cancer | AAC | 0.06 | 0.09 |
| mRNA | etoposide | GDSC1000 | pan-cancer | AAC | 0.059 | 0.09 |
| mRNA | decitabine:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.055 | 0.09 |